Table 1.
Patient characteristics.
| Age (years) | |
|---|---|
| Median (IQR) | 67.0 (63.8–72.0) |
| Mean (SD) | 67.2 (5.7) |
| Range | 44.0-77.0 |
| Prostate-specific antigen (ng/ml) | |
| Median (IQR) | 9.4 (7.1–12.5) |
| Mean (SD) | 11.4 (7.6) |
| Range | 0.1–47.7 |
| Clinical stage (%) | |
| ≤T2a | 148 (69.8%) |
| T2b/c | 44 (20.8%) |
| T3 | 20 (9.4%) |
| Biopsy Gleason Score (%) | |
| ≤6 | 42 (19.8%) |
| 7 (3 + 4) | 75 (35.4%) |
| 7 (4 + 3) | 39 (18.4%) |
| >7 | 56 (26.4%) |
| No. of positive cores | |
| Median (IQR) | 4.0 (2.0–7.0) |
| Mean (SD) | 4.8 (3.3) |
| Range | 1.0–14.0 |
| Maximum percentage of cancer pre-core (%) | |
| Median (IQR) | 50.0 (20.0–80.0) |
| Mean (SD) | 50.4 (30.0) |
| Range | 5.0–100.0 |
| The interval from biopsy to SWE (days) | |
| Median (IQR) | 102.5 (83–118) |
| Mean (SD) | 102.6 (27.3) |
| Range | 46–189 |
| The interval from biopsy to MRI (days) | |
| Median (IQR) | 43 (35–48) |
| Mean (SD) | 43.8 (11.2) |
| Range | 21–78 |
| Radical prostatectomy weight (g) | |
| Median (IQR) | 59.5 (47.5–76.5) |
| Mean (SD) | 66.9 (29.4) |
| Range | 31.0–207.0 |